Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Immunogenicity, Efficacy and Safety of Treatment With Human-cl-rhFVIII in Previously Untreated Patients With Severe Hemophilia A

NCT01712438 is registered in ClinicalTrials.gov with Octapharma as lead sponsor.

NCT NCT01712438
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01712438 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Immunogenicity, Efficacy and Safety of Treatment With Human-cl-rhFVIII in Previously Untreated Patients With Severe Hemophilia A
Lead sponsor
Octapharma
Phase
Phase 3
Overall status
Completed
Start date
February 28, 2013
Completion date
December 20, 2019
Enrollment
110 (actual)
Sites
37

Conditions

As the registry lists them; a condition with its own page is linked.

severe hemophilia a